Recruiting

Aspirin for Postpartum Patients With Preeclampsia

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood…

ClinicalTrials.gov IDNCT05924971

PhasePHASE2

Enrollment86

SponsorMemorialCare Health System

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Preeclampsia Postpartum

About this study

Interventions

Drug: Aspirin 81Mg Ec Tab — Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.

Primary outcomes

Reduction in sFlt-1 (1 week postpartum)

Eligibility information

Inclusion Criteria: * Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria. * Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic. Exclusion Criteria: * Patient age \<18 years old * Non-English or Non-Spanish speaking * Chronic hypertension diagnosed before 20 weeks' gestation * Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction) * Aspirin prescribed postpartum for any other medical condition * Bleeding disorder * Breastfeeding an infant with thrombocytopenia

Study locations

Miller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach, Long Beach, California 90740 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.